Human Papillomavirus (HPV) Vaccine Market Forecast to 2028
The human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028; it is expected to grow at a CAGR of 5.0% from 2022 to 2028.
Human papillomaviruses (HPV) is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of HPV have been characterized. The increasing prevalence of various cancers caused by HPV is expected to drive the human papillomavirus (HPV) vaccine market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), HPV is the most common sexually transmitted infection in the US. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to HPV infection. CDC also states that about 14 million people are newly infected by the virus every year in the US.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Papillomavirus (HPV) Vaccine Market: Strategic Insights
Market Size Value in US$ 4,273.84 million in 2022 Market Size Value by US$ 5,730.50 million by 2028 Growth rate CAGR of 5.0% from 2022 to 2028. Forecast Period 2022-2028 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Papillomavirus (HPV) Vaccine Market: Strategic Insights
| Market Size Value in | US$ 4,273.84 million in 2022 |
| Market Size Value by | US$ 5,730.50 million by 2028 |
| Growth rate | CAGR of 5.0% from 2022 to 2028. |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
The global human papillomavirus (HPV) vaccine market is segmented on the basis of type, dosage, age, distribution channel, and geography. The market, by region, is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the human papillomavirus (HPV) vaccine market, emphasizing on various parameters such as market trends, technological advancements, and market dynamics. It also includes the competitive landscape analysis of leading market players across the globe.
Market Insight
Increase in Prevalence of HPV Associated Diseases
Increase in Prevalence of HPV Associated Diseases
Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is likely to drive the market's growth.
In women, cervical cancer is the fourth most common cancer. As per the World Health Organization (WHO) report estimation, in 2018, an estimated 570,000 women worldwide had cervical cancer, and about 311,000 female deaths were due to cervical cancer. Additionally, the American Society of Clinical Oncology (ASCO) estimated that around 14,100 cases of invasive cervical cancer would be registered in the US alone. Further, as per the report, 'Cervical cancer burden in EU-27,' in 2020, there were 30,447 new cases and 13,437 deaths due to cervical cancer in women.
Further, as per the Centers for Disease Control and Prevention (CDC), in 2018, there were around 43 million HPV infections in the US. The CDC also estimated that about 19,400 women and 12,100 men annually suffer from cancers caused by HPV. Further, as per the National Foundation for Infectious Diseases (NFID), there are around 14 million new HPV infection cases in the US every year. In addition, as per the report, titled 'Human Papillomavirus and Related Diseases Report-Europe,' in 2020, 8,449 women and 4,327 men had anal cancer in Europe.
Such a high incidence of HPV associated infections across the world is likely to favor the overall market growth in the coming years.
Type-Based Insights
Based on type, the human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment holds the largest market share. However, the market for the 9-valent HPV vaccine segment is expected to witness the rapid growth from 2022 to 2028. The quadrivalent human papillomavirus (HPV) vaccine protects against infection with HPV types 6, 11, 16, and 18, which are responsible for 70% to 80% of cervical cancers and at least 90% of genital warts cases. The vaccine reduces the risk of genital warts and the precursor lesions of cervical, vaginal, and vulvar cancers caused by the virus.
Dosage-Based Insights
Based on dosage, the human papillomavirus (HPV) vaccine market is segmented into 2 dose and 3 dose. In 2022, the 2 dose segment accounts for a larger market share.
Age-Based Insights
The global human papillomavirus (HPV) vaccine market, based on age, is segmented into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period.
Application–Based Insights
In terms of application, the global human papillomavirus (HPV) vaccine market is segmented into HPV-attributable cancers and genital warts. The HPV-attributable cancers segment holds a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period.
Distribution Channel–Based Insights
On the basis of distribution channel, the global human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment holds the largest share of the market in 2022, and the school-based health centers segment is anticipated to register the highest CAGR in the market during the forecast period.
The COVID-19 pandemic is likely to have longer-term consequences on the HPV vaccine business. Many primary care clinics in the US have continued to operate at a reduced capacity to abide by social distancing measures and adopt stringent cleaning protocols. A reduction in in-person office visits limits opportunities for vaccine providers to discuss and deliver vaccines. Barriers in transportation are likely to harm HPV vaccination; pharma and biotech companies traditionally find it difficult to market vaccines among the masses because of resistance received from parents and the absence of widespread awareness about school entry requirements that support other adolescent vaccines. The available evidence indicates that the COVID-19 pandemic has dramatically disrupted the delivery of HPV vaccines in 2020 and 2021. Early reports by CDC, suggest that ordering and billing dropped by >70% in March 2020. Furthermore, a 25–50% decrease in HPV vaccine orders continued in June 2020, in contrast to other early childhood-vaccine orders that resurged to near pre-pandemic levels. Although the revival of the HPV vaccine market is in progress, available data suggest that a short-term decline in HPV vaccination coverage will be substantial, and the demand for HPV vaccine will grow across North America in long term.
Human Papillomavirus (HPV) Vaccine Market Report Scope
Companies commonly adopt product launches and expansion strategies to expand their footprint worldwide, meet the growing demand, and expand their product portfolio. The players operating in the global human papillomavirus (HPV) vaccine market implement the strategy of product innovation for changing customer demand worldwide, which also permits them to maintain their brand name globally.
- In May 2022, China’s National Medical Products Administration (NMPA) approved GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls from 9 to 14 years to prevent cervical cancer. Cervarix is a recombinant, noninfectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine.
- n May 2022, Serum Institute of India announced the development of a tetravalent HPV vaccine including L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of ~90% against papillomavirus. The vaccine is currently under development.
- In May 2020, Shanghai Bovax Biotechnology collaborated with Chongoing Bovax Biopharmaceutical to evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccines.
By geography, the human papillomavirus (HPV) vaccine market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South & Central America). GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders are among the leading companies operating in the market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Dosage, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Bahrain, Belarus, Brazil, Canada, Chile, China, Colombia, Egypt, France, Germany, Guatemala, India, Indonesia, Iran, Italy, Japan, Kuwait, Malaysia, Mexico, New Zealand, Peru, Philippines, Russian Federation, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Thailand, Turkey, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The human papillomavirus vaccine market majorly consists of the players such Merck & Co. In., GSK, Serum Institute of India, Walvax Biotechnologies, Innovax, Vaccitech, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, R-Pharm, Shanghai Bowei, and Bioleaders amongst others.
The human papillomavirus vaccine market, by type, is bifurcated 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment held the largest share of the market, by type. However, the 9-valent HPV vaccine segment is expected to witness the fastest growth during 2022 to 2028.
Driving factor such as increase in prevalence of HPV associated diseases and initiatives taken by global health organizations are likely to have a positive impact on the growth of the global human papillomavirus (HPV) vaccines market. Whereas factors, such as growing number of HPV awareness programs, are likely to create a growth opportunity on the HPV vaccines market in the near future.
Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection. CDC also states that about 14 million people are newly infected by human papillomavirus every year in the U.S.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Human Papillomavirus (HPV) Vaccines Market – By Type
1.3.2 Global Human Papillomavirus (HPV) Vaccines Market – By Dosage
1.3.3 Global Human Papillomavirus (HPV) Vaccines Market – By Age
1.3.4 Global Human Papillomavirus (HPV) Vaccines Market – By Application
1.3.5 Global Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel
1.3.6 Global Human Papillomavirus (HPV) Vaccines Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Human Papillomavirus (HPV) Vaccine Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of HPV Associated Diseases
5.1.2 Initiatives Taken by Global Health Organizations
5.2 Market Restraints
5.2.1 High Cost of HPV Vaccines
5.3 Market Opportunities
5.3.1 Growing Number of HPV Awareness Programs
5.4 Future Trends
5.4.1 Advancements in HPV Diagnostics Tests
5.5 Impact Analysis
6. Human Papillomavirus (HPV) Vaccine Market– Global Analysis
6.1 Global Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
6.2 Global Human Papillomavirus (HPV) Vaccine Market, By Geography - Forecast and Analysis
6.3 Global Human Papillomavirus (HPV) Vaccine Market – Market Potential Analysis, By Region
6.4 Global Human Papillomavirus (HPV) Vaccine Market – Pricing Analysis, By Region
6.5 Global Human Papillomavirus (HPV) Vaccine Market – Patent Status
6.6 Growth Strategy Analysis
6.7 Performance of Key Players
6.7.1 Merck & Co., In.
6.7.2 GSK
7. Global Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast To 2028– by Type
7.1 Overview
7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)
7.3 9-valent HPV vaccine
7.3.1 Overview
7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.4 Quadrivalent HPV vaccine
7.4.1 Overview
7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.5 Bivalent HPV Vaccine
7.5.1 Overview
7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
8. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Dosage
8.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
8.2 2 Dose
8.2.1 Overview
8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
8.3 3 Dose
8.3.1 Overview
8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
9. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Age
9.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
9.2 9 to 14 Years
9.2.1 Overview
9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
9.3 to 45 Years
9.3.1 Overview
9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
10. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Application
10.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
10.2 HPV-attributable Cancer
10.2.1 Overview
10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
10.3 Genital Warts
10.3.1 Overview
10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
11. Global Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 – by End User
11.1 Overview
11.2 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
11.3 Doctor Office
11.3.1 Overview
11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
11.4 Community Health Clinics
11.4.1 Overview
11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
11.5 School-based Health Centers
11.5.1 Overview
11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
11.6 Health Departments
11.6.1 Overview
11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)
11.7 Hospitals
11.7.1 Overview
11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
11.8 Others
11.8.1 Overview
11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)
12. Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 Geographical Analysis
12.1 North America: Human Papillomavirus (HPV) Vaccine Market
12.1.1 Overview
12.1.2 North America: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.3 North America: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.4 North America: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.5 North America: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.6 North America: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.7 North America: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.1.8 North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
12.1.8.1 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.1 Overview
12.1.8.1.2 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.3 US: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.8.1.4 US: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.8.1.5 US: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.8.1.6 US: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.8.1.7 US: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.1.8.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.1 Overview
12.1.8.2.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.3 Canada: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.8.2.4 Canada: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.8.2.5 Canada: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.8.2.6 Canada: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.8.2.7 Canada: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.1.8.3 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.1 Overview
12.1.8.3.2 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.3 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.8.3.4 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.8.3.5 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.8.3.6 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.8.3.7 Mexico: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.2 Europe: Human Papillomavirus (HPV) Vaccine Market
12.2.1 Overview
12.2.2 Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.3 Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.4 Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.5 Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.6 Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.7 Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8 Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
12.2.8.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.2 Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.3 Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.4 Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.5 Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.1.6 Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.2 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.1 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.2 France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.3 France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.4 France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.5 France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.2.6 France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.3 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.1 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.2 UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.3 UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.4 UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.5 UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.3.6 UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.4 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.1 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.2 Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.3 Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.4 Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.5 Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.4.6 Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.5 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.1 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.2 Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.3 Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.4 Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.5 Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.5.6 Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.6 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.1 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.2 Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.3 Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.4 Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.5 Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.6.6 Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.7 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.1 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.2 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.3 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.4 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.5 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.7.6 Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.2.8.8 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.1 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.2 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.3 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.4 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.5 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.2.8.8.6 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
12.3 Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028
12.3.1 Overview
12.3.2 Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.3 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.4 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.5 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.6 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.7 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Country (2022 & 2028)
12.3.8.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.1.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.1.2 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.1.3 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.1.4 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.1.5 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.1.6 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.2.1 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.2.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.2.3 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.2.4 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.2.5 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.2.6 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.3.1 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.3.2 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.3.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.3.4 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.3.5 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.3.6 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.4.1 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.4.2 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.4.3 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.4.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.4.5 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.4.6 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.5.1 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.5.2 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.5.3 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.5.4 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.5.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.5.6 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.6 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.6.1 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.6.2 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.6.3 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.6.4 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.6.5 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.6.6 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.7 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.7.1 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.7.2 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.7.3 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.7.4 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.7.5 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.7.6 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.8 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.8.1 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.8.2 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.8.3 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.8.4 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.8.5 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.8.6 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.9 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.9.1 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.9.2 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.9.3 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.9.4 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.9.5 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.9.6 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.10 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.10.1 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.10.2 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.10.3 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.10.4 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.10.5 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.10.6 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.11 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.11.1 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.11.2 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.11.3 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.11.4 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.11.5 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.11.6 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.3.8.12 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.3.8.12.1 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market– Revenue and Forecast to 2028 (US$ Million)
12.3.8.12.2 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.3.8.12.3 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.3.8.12.4 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.3.8.12.5 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.3.8.12.6 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.4 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast To 2028
12.4.1 Overview
12.4.2 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.3 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.4 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.5 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.6 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.7 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
12.4.8.1 UAE: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.1.1 Overview
12.4.8.1.2 UAE: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.1.3 UAE: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.1.4 UAE: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.1.5 UAE: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.1.6 UAE: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.1.7 UAE: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.2.1 Overview
12.4.8.2.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.2.3 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.2.4 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.2.5 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.2.6 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.2.7 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.3 South Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.3.1 Overview
12.4.8.3.2 South Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.3.3 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.3.4 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.3.5 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.3.6 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.3.7 South Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.4 Iran: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.4.1 Overview
12.4.8.4.2 Iran: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.4.3 Iran: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.4.4 Iran: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.4.5 Iran: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.4.6 Iran: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.4.7 Iran: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.5 Turkey: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.5.1 Overview
12.4.8.5.2 Turkey: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.5.3 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.5.4 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.5.5 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.5.6 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.5.7 Turkey: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.6.1 Overview
12.4.8.6.2 Kuwait: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.6.3 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.6.4 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.6.5 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.6.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.6.7 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.7.1 Overview
12.4.8.7.2 Bahrain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.7.3 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.7.4 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.7.5 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.7.6 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.7.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.8 Egypt: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.8.1 Overview
12.4.8.8.2 Egypt: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.8.3 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.8.4 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.8.5 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.8.6 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.8.7 Egypt: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.4.8.9 Rest of Middle the East and Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.4.8.9.1 Overview
12.4.8.9.2 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.4.8.9.3 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.4.8.9.4 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.4.8.9.5 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.4.8.9.6 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.4.8.9.7 Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.5 South and Central America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028
12.5.1 Overview
12.5.2 South & Central America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.3 South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.4 South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.5 South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.6 South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.7 South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8 South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)
12.5.8.1 Argentina Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.1.1 Overview
12.5.8.1.2 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.1.3 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.1.4 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.1.5 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.1.6 Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.1.7 Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.2.1 Overview
12.5.8.2.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.2.3 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.2.4 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.2.5 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.2.6 Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.2.7 Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.3.1 Overview
12.5.8.3.2 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.3.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.3.4 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.3.5 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.3.6 Chile: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.3.7 Chile: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.4.1 Overview
12.5.8.4.2 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.4.3 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.4.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.4.5 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.4.6 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.4.7 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.5.1 Overview
12.5.8.5.2 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.5.3 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.5.4 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.5.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.5.6 Peru: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.5.7 Peru: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.6 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.5.8.6.1 Overview
12.5.8.6.2 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.6.3 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.6.4 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.6.5 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.6.6 Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.6.7 Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.5.8.7 Rest of South and Central America: Human Papillomavirus (HPV) Vaccine Market– Revenue and Forecast to 2028 (USD Million)
12.5.8.7.1 Overview
12.5.8.7.2 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.7.3 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.5.8.7.4 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.5.8.7.5 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.5.8.7.6 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.5.8.7.7 Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
13. Impact Of COVID-19 Pandemic on Human Papillomavirus (HPV) Vaccine Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
13.2 Europe: Impact Assessment of COVID-19 Pandemic
13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13.5 South & Central America: Impact Assessment of COVID-19 Pandemic
14. Human Papillomavirus (HPV) Vaccine Market–Industry Landscape
14.1 Overview
14.2 Growth Strategies in the HPV Vaccines Market, 2021-2028
14.3 Inorganic Growth Strategies
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Merck & Co., Inc.
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 GlaxoSmithKline plc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 INNOVAX
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Serum Institute of India Pvt. Ltd
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Walvax Biotechnology Co., Ltd.
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 INOVIO Pharmaceuticals
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Vaccitech
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 2A Pharma
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 ChengDu Institute of Biological Products Co., Ltd.
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Sanofi
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 R-Pharm
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Shanghai Bowei
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 BioLeaders
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (USD Million)
Table 3. North America Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (USD Million)
Table 4. North America Human Papillomavirus (HPV) Vaccine Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. US Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 8. US Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 9. US Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 10. US Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 23. Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 24. Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 26. Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 27. Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 28. Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 29. Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 30. Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 31. France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 32. France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 33. France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 34. France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 35. France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 36. UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 37. UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 38. UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 39. UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 40. UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 41. Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 42. Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 43. Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 44. Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 45. Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 46. Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 47. Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 48. Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 49. Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 50. Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 51. Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 52. Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 53. Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 54. Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 55. Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 56. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 57. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 58. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 59. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 60. Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 66. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 67. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 68. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 69. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 70. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 71. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 72. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 73. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 74. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 75. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 76. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 77. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 78. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 79. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 80. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 81. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 82. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 83. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 84. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 85. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 86. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 87. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 88. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 89. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 90. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 91. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 92. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 93. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 94. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 95. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 96. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 97. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 98. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 99. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 100. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 101. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 102. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 103. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 104. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 105. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 106. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 107. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 108. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 109. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 110. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 111. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 112. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 113. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 114. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 115. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 116. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 117. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 118. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 119. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 120. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 121. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 122. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 123. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 124. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 125. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 126. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
Table 127. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
Table 128. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
Table 129. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 130. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
Table 131. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 132. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (USD Million)
Table 133. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (USD Million)
Table 134. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 135. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 136. UAE Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 137. UAE Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 138. UAE Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 139. UAE Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 140. UAE Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 141. Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 142. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 143. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 144. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 145. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 146. South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 147. South Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 148. South Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 149. South Africa Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 150. South Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 151. Iran: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 152. Iran Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 153. Iran Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 154. Iran Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 155. Iran Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 156. Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 157. Turkey Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 158. Turkey Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 159. Turkey Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 160. Turkey Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 161. Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 162. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 163. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 164. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 165. Kuwait Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 166. Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 167. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 168. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 169. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 170. Bahrain Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 171. Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 172. Egypt Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 173. Egypt Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 174. Egypt Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 175. Egypt Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 176. Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 177. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 178. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 179. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 180. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 181. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million).
Table 182. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 183. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 184. South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 185. South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 186. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 187. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 188. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 189. Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 190. Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 191. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 192. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 193. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 194. Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 195. Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 196. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 197. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 198. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 199. Chile: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 200. Chile: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 201. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 202. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 203. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 204. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 205. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 206. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 207. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 208. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 209. Peru: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 210. Peru: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 211. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 212. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 213. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 214. Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 215. Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 216. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 217. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 218. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 219. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 220. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 221. Recent Inorganic Growth Strategies in the HPV Vaccines Market
Table 222. Recent Organic Growth Strategies in the HPV Vaccines Market
Table 223. Glossary of Terms
LIST OF FIGURES
Figure 1. Human Papillomavirus (HPV) Vaccines Market Segmentation
Figure 2. Human Papillomavirus (HPV) Vaccines Market, By Region
Figure 3. Global Human Papillomavirus (HPV) Vaccine Market Overview
Figure 4. 9-Valent HPV Vaccine Segment Held Largest Share of Type Segment in Human Papillomavirus (HPV) Vaccines Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Human Papillomavirus (HPV) Vaccine Market, by Geography (US$ Million)
Figure 7. Global Human Papillomavirus (HPV) Vaccine Market - Leading Country Markets (US$ Million)
Figure 8. Global Human Papillomavirus (HPV) Vaccine Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South And Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Global Human Papillomavirus (HPV) Vaccines Market Impact Analysis of Driver and Restraints
Figure 16. Global Human Papillomavirus (HPV) Vaccine Market– Revenue Forecast and Analysis – 2022 - 2028
Figure 17. Global HPV Vaccines Market – By Geography Forecasts And Analysis – 2022- 2028
Figure 18. Global Human Papillomavirus (HPV) Vaccine Market – Market Potential Analysis, By Region
Figure 19. Global Human Papillomavirus (HPV) Vaccine Market – Pricing Analysis, By Region
Figure 20. Global Human Papillomavirus (HPV) Vaccine Market – Patent Status
Figure 21. Global HPV Vaccines market – Growth Strategy Analysis
Figure 22. By Type: Market Analysis and Forecast 2022 and 2028 (%)
Figure 23. 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 24. Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
Figure 27. 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
Figure 30. 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
Figure 33. HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
Figure 36. Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
Figure 37. Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 38. School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 39. Health Departments Market Revenue and Forecast to 2028 (US$ Million)
Figure 40. Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 41. Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 42. North America: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)
Figure 43. North America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 44. North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
Figure 45. US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Europe: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)
Figure 49. Europe: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 50. Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
Figure 51. Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 53. UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 54. Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 55. Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 56. Russia Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 57. Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 58. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 59. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Overview, by Country (2022)
Figure 60. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 61. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Country (2022 & 2028)
Figure 62. Japan Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 63. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 64. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 65. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 66. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 67. New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 68. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 69. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 70. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 71. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 72. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Figure 73. Rest Of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market– Revenue and Forecast to 2028 (US$ Million)
Figure 74. Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)
Figure 75. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 76. Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
Figure 77. UAE: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 78. Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 79. South Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 80. Iran: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 81. Turkey: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 82. Kuwait: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 83. Bahrain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 84. Egypt: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 85. Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 86. South & Central America Human Papillomavirus (HPV) Vaccine Market Overview, by Country (2022)
Figure 87. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 88. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)
Figure 89. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 90. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 91. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 92. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 93. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 94. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 95. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 96. Impact of COVID-19 Pandemic in North American Country Markets
Figure 97. Impact of COVID-19 Pandemic in European Country Markets
Figure 98. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
Figure 99. Impact of COVID-19 Pandemic on Middle East & African Countries
Figure 100. Impact of COVID-19 Pandemic on South & Central America Countries
Figure 101. Growth Strategies in the HPV Vaccines Market, 2021-2028
The List Of Companies - HPV Vaccines Market
- Merck & Co. In.
- GSK
- Serum Institute of India
- Walvax Biotechnologies
- Innova
- Vaccitech
- Innovio Pharmaceuticals
- Chengdu Institute of Biological Products Co., Ltd.
- Sanofi
- R-Pharm
- Shanghai Bowei
- Bioleaders
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For